Trevi Therapeutics (TRVI) Interest Expenses (2018 - 2024)
Trevi Therapeutics' quarterly Interest Expenses came in at $1000.0 in Q4 2024, down 75.0% year-on-year from $4000.0 in Q1 2024, and little changed quarter-over-quarter from $1000.0 in Q3 2024.
Trevi Therapeutics has reported Interest Expenses for 6 years, with the latest figure at $1000.0 in Q4 2024.
- For the quarter ending Q4 2024, Interest Expenses fell 75.0% year-over-year to $1000.0; the trailing twelve-month figure through Sep 2025 stood at $1000.0 (down 85.71% YoY), and the FY2024 full-year result was $4000.0, down 98.98% from the prior year.
- Interest Expenses for Q4 2024 stood at $1000.0, roughly flat from $1000.0 in the prior quarter.
- The five-year high for Interest Expenses was $827000.0 in Q4 2021, with the low at $1000.0 in Q1 2024.
- Average Interest Expenses over 5 years is $211833.3, with a median of $252500.0 recorded in 2022.
- Year-over-year, Interest Expenses jumped 168.51% in 2021 and plunged 99.57% in 2024.
- Tracing TRVI's Interest Expenses over 5 years: stood at $308000.0 in 2020, then soared by 168.51% to $827000.0 in 2021, then sank by 66.87% to $274000.0 in 2022, then slumped by 98.54% to $4000.0 in 2023, then slumped by 75.0% to $1000.0 in 2024.
- The last three Interest Expenses figures came in at $1000.0 (Q4 2024), $1000.0 (Q3 2024), and $1000.0 (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 4,000.00 |
| Dec 31, 2023 | 4,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 153,000.00 |
| Jun 30, 2023 | 153,000.00 |
| Mar 31, 2023 | 231,000.00 |
| Mar 31, 2023 | 231,000.00 |
| Dec 31, 2022 | 274,000.00 |
| Dec 31, 2022 | 274,000.00 |
| Sep 30, 2022 | 292,000.00 |
| Sep 30, 2022 | 292,000.00 |
| Jun 30, 2022 | 295,000.00 |
| Jun 30, 2022 | 295,000.00 |
| Mar 31, 2022 | 302,000.00 |
| Mar 31, 2022 | 302,000.00 |
| Dec 31, 2021 | 827,000.00 |
| Dec 31, 2021 | 827,000.00 |
| Sep 30, 2021 | 303,000.00 |
| Sep 30, 2021 | 303,000.00 |
| Jun 30, 2021 | 375,000.00 |
| Jun 30, 2021 | 375,000.00 |
| Mar 31, 2021 | 294,000.00 |
| Mar 31, 2021 | 294,000.00 |
| Dec 31, 2020 | 308,000.00 |
| Dec 31, 2020 | 308,000.00 |
| Sep 30, 2020 | 148,000.00 |
| Sep 30, 2020 | 148,000.00 |
| Jun 30, 2018 | 51,000.00 |
| Jun 30, 2018 | 51,000.00 |
| Mar 31, 2018 | 123,000.00 |
| Mar 31, 2018 | 123,000.00 |